Skip to content

Five9 FIVN Impairment of long-lived assets

Impairment of long-lived assets at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0
UBS
United BanksharesUBSI
$13.75K-74.9%
APO
Apogee EnterprisesAPOG
$4.06M-46.8%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$0-100%
Encore Capital Group logo
Encore Capital GroupECPG
$0-100%
WaFd, Inc. logo
WaFd, Inc.WAFD
$0-100%

Other financials

Income statement

See full
Revenue$305.3M+9.2%
Gross profit$170.5M+10.9%
Operating income$18.5M+441%
Net income$18.4M+3,097%
EPS (diluted)$0.21+2,000%

Balance sheet

See full
Cash & equivalents$275.1M-26.1%
Total debt$72.1M-85.9%
Total equity$829.6M+24.9%
Total assets$1.9B-10.7%

Cash flow

See full
Operating cash flow$63.9M+32.1%
CapEx$5.3M+11.5%
Free cash flow$58.7M+34.3%

Valuation

See full
Market cap$1.49B-27.2%
Enterprise value$1.29B-41.1%
P/E26.1×
P/S1.3×-0.6×

Profitability

See full
Gross margin55.3%+0.8pp
Operating margin4.5%+3.1pp
Net margin4.9%+4.5pp
FCF margin18.4%+6.9pp

Returns & leverage

See full
Return on equity7.7%+6.9pp
Debt / equity0.1×-0.7×
Current ratio4.5×+2.5×

Where this comes from

Reported directly by Five9 in its filing.

Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.

The official record: Five9’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Five9's impairment of long-lived assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Five9's impairment of long-lived assets?
Five9 (FIVN) reported impairment of long-lived assets of $136K in Q1 2026.
How has Five9's impairment of long-lived assets changed year-over-year?
Five9's impairment of long-lived assets decreased by 57.8% year-over-year, from $322K to $136K.